See more : Kubota Corporation (KUBTF) Income Statement Analysis – Financial Results
Complete financial analysis of SUSMED,Inc. (4263.T) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of SUSMED,Inc., a leading company in the Healthcare industry within the Healthcare sector.
- Spartan Delta Corp. (DALXF) Income Statement Analysis – Financial Results
- Showa System Engineering Corporation (4752.T) Income Statement Analysis – Financial Results
- Amicorp FS (UK) plc (AMIF.L) Income Statement Analysis – Financial Results
- Bioventix PLC (BVXP.L) Income Statement Analysis – Financial Results
- REN – Redes Energéticas Nacionais, SGPS, S.A. (RENE.LS) Income Statement Analysis – Financial Results
SUSMED,Inc. (4263.T)
About SUSMED,Inc.
SUSMED,Inc. develops and sells therapeutic applications in Japan. It develops smartphone based digital therapeutics applications for diseases with insomnia, breast cancer, and kidney disease. The company also develops and sells development platform for therapeutic apps and clinical trial systems. In addition, it offers medical data analysis and consulting services. The company was incorporated in 2015 and is headquartered in Tokyo, Japan.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 342.58M | 530.65M | 316.87M | 115.49M | 34.89M |
| Cost of Revenue | 11.73M | 7.99M | 10.37M | 9.76M | 1.55M |
| Gross Profit | 330.85M | 522.67M | 306.50M | 105.73M | 33.34M |
| Gross Profit Ratio | 96.58% | 98.49% | 96.73% | 91.55% | 95.56% |
| Research & Development | 243.35M | 176.31M | 226.37M | 249.14M | 86.37M |
| General & Administrative | 452.48M | 394.67M | 309.28M | 190.01M | 107.70M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 452.48M | 394.67M | 309.28M | 190.01M | 107.70M |
| Other Expenses | 0.00 | 4.40M | 36.01M | 62.34M | 71.91M |
| Operating Expenses | 695.83M | 570.98M | 535.65M | 439.15M | 194.07M |
| Cost & Expenses | 707.56M | 578.97M | 546.03M | 448.91M | 195.62M |
| Interest Income | 0.00 | 2.00K | 2.00K | 2.00K | 4.00K |
| Interest Expense | 0.00 | 407.00K | 24.30M | 0.00 | 0.00 |
| Depreciation & Amortization | 5.99M | 5.55M | 2.05M | 114.00K | 180.00K |
| EBITDA | -358.99M | -43.00M | -228.00M | -275.60M | -96.45M |
| EBITDA Ratio | -104.79% | -7.08% | -66.71% | -284.59% | -437.78% |
| Operating Income | -364.98M | -48.32M | -229.15M | -333.42M | -160.73M |
| Operating Income Ratio | -106.54% | -9.10% | -72.32% | -288.70% | -460.70% |
| Total Other Income/Expenses | 8.78M | -1.22M | -4.01M | 57.71M | 64.10M |
| Income Before Tax | -356.21M | -49.54M | -233.16M | -275.71M | -96.63M |
| Income Before Tax Ratio | -103.98% | -9.34% | -73.58% | -238.74% | -276.98% |
| Income Tax Expense | 1.21M | 1.21M | 319.00K | 1.84M | 290.00K |
| Net Income | -357.42M | -50.75M | -233.48M | -277.55M | -96.92M |
| Net Income Ratio | -104.33% | -9.56% | -73.68% | -240.33% | -277.81% |
| EPS | -21.41 | -3.09 | -15.90 | -21.69 | -6.23 |
| EPS Diluted | -21.41 | -3.09 | -15.90 | -21.69 | -6.23 |
| Weighted Avg Shares Out | 16.69M | 16.40M | 14.68M | 12.79M | 15.55M |
| Weighted Avg Shares Out (Dil) | 16.69M | 16.40M | 14.68M | 12.79M | 15.55M |
Source: https://incomestatements.info
Category: Stock Reports